摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4Z)-4-((dimethylamino)methylene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one | 65644-13-5

中文名称
——
中文别名
——
英文名称
(4Z)-4-((dimethylamino)methylene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one
英文别名
(Z)-4-((dimethylamino)methylene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one;4-dimethylaminomethylene-5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one;(4Z)-4-[(dimethylamino)methylidene]-3-methyl-1-phenyl-4,5-dihydro-1H-pyrazol-5-one;(4Z)-4-(dimethylaminomethylidene)-5-methyl-2-phenylpyrazol-3-one
(4Z)-4-((dimethylamino)methylene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one化学式
CAS
65644-13-5
化学式
C13H15N3O
mdl
——
分子量
229.282
InChiKey
ZKMQJGARZNSQNV-XFXZXTDPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    309.1±52.0 °C(Predicted)
  • 密度:
    1.11±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    35.9
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-Fluoro-4-{[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy}-aniline(4Z)-4-((dimethylamino)methylene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one溶剂黄146 作用下, 以72%的产率得到(4Z)-4-(((3-fluoro-4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)oxy)phenyl)amino)methylene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one
    参考文献:
    名称:
    Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents
    摘要:
    Two series of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 2,4-imidazolinedione/pyrazolone scaffold were designed, synthesized and evaluated for their c-Met kinase inhibition and cytotoxicity against HT-29, H460, A549, MKN-45, and U87MG cancer cell lines in vitro. The pharmacological data indicated that most of the tested compounds showed moderate to significant cytotoxicity and high selectivity against HT-29, H460 and A549 cancer cell lines as compared with foretinib. The SAR analyses indicated that compounds with halogen groups, especially trifluoromethyl groups at 2-position on the phenyl ring (moiety B) were more effective. In this study, a promising compound 17 (c-Met IC50 = 2.20 nM, a multi-target tyrosine kinase inhibitor) showed the most potent antitumor activities with IC50 values of 0.14 mu M, 0.18 mu M, 0.09 mu M, 0.03 mu M, and 1.06 mu M against HT-29, H460, A549, MKN-45, and U87MG cell lines, respectively. (C) 2014 Elsevier Inc. All rights reserved.
    DOI:
    10.1016/j.bioorg.2014.07.011
  • 作为产物:
    描述:
    苯胺盐酸溶剂黄146 、 sodium nitrite 作用下, 以 为溶剂, 反应 5.5h, 生成 (4Z)-4-((dimethylamino)methylene)-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one
    参考文献:
    名称:
    Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents
    摘要:
    Two series of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 2,4-imidazolinedione/pyrazolone scaffold were designed, synthesized and evaluated for their c-Met kinase inhibition and cytotoxicity against HT-29, H460, A549, MKN-45, and U87MG cancer cell lines in vitro. The pharmacological data indicated that most of the tested compounds showed moderate to significant cytotoxicity and high selectivity against HT-29, H460 and A549 cancer cell lines as compared with foretinib. The SAR analyses indicated that compounds with halogen groups, especially trifluoromethyl groups at 2-position on the phenyl ring (moiety B) were more effective. In this study, a promising compound 17 (c-Met IC50 = 2.20 nM, a multi-target tyrosine kinase inhibitor) showed the most potent antitumor activities with IC50 values of 0.14 mu M, 0.18 mu M, 0.09 mu M, 0.03 mu M, and 1.06 mu M against HT-29, H460, A549, MKN-45, and U87MG cell lines, respectively. (C) 2014 Elsevier Inc. All rights reserved.
    DOI:
    10.1016/j.bioorg.2014.07.011
点击查看最新优质反应信息

文献信息

  • SMIRNOVA, N. P.;KVITKO, I. YA.;ELTSOV, A. V., ZH. ORGAN. XIMII, 1986, 22, N 3, 650-660
    作者:SMIRNOVA, N. P.、KVITKO, I. YA.、ELTSOV, A. V.
    DOI:——
    日期:——
  • TOKMAKOV G. P.; ZEMLYANOVA T. G.; GRANDBERG I. I., IZV. TIMIRYAZEV. S.-X. AKAD.,(1986) N 5, 166-169
    作者:TOKMAKOV G. P.、 ZEMLYANOVA T. G.、 GRANDBERG I. I.
    DOI:——
    日期:——
  • WRZECIONO U.; SZOSTAK-RZEPIAK B., PHARMAZIE <PHAR-AT>, 1975, 30, NO 9, 582-585
    作者:WRZECIONO U.、 SZOSTAK-RZEPIAK B.
    DOI:——
    日期:——
  • Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents
    作者:Shunguang Zhou、Jianguo Ren、Mingmei Liu、Lixiang Ren、Yajing Liu、Ping Gong
    DOI:10.1016/j.bioorg.2014.07.011
    日期:2014.12
    Two series of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 2,4-imidazolinedione/pyrazolone scaffold were designed, synthesized and evaluated for their c-Met kinase inhibition and cytotoxicity against HT-29, H460, A549, MKN-45, and U87MG cancer cell lines in vitro. The pharmacological data indicated that most of the tested compounds showed moderate to significant cytotoxicity and high selectivity against HT-29, H460 and A549 cancer cell lines as compared with foretinib. The SAR analyses indicated that compounds with halogen groups, especially trifluoromethyl groups at 2-position on the phenyl ring (moiety B) were more effective. In this study, a promising compound 17 (c-Met IC50 = 2.20 nM, a multi-target tyrosine kinase inhibitor) showed the most potent antitumor activities with IC50 values of 0.14 mu M, 0.18 mu M, 0.09 mu M, 0.03 mu M, and 1.06 mu M against HT-29, H460, A549, MKN-45, and U87MG cell lines, respectively. (C) 2014 Elsevier Inc. All rights reserved.
查看更多

同类化合物

(4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] 香豆素-6-羧酸 锌离子载体IV 钐(III) 离子载体 II 苯,(2,2-二氟乙烯基)- 聚二硫二噻唑烷 缩胆囊肽9 甲酰乙内脲 甲巯咪唑 甲基羟甲基油基噁唑啉 甲基5-羟基-3,5-二甲基-4,5-二氢-1H-吡唑-1-羧酸酯 甲基5-甲基-4,5-二氢-1H-吡唑-1-羧酸酯 甲基5-氰基-4,5-二氢-1,2-恶唑-3-羧酸酯 甲基5-乙炔基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-甲基-5-氧代-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-甲基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4-乙炔基-4,5-二氢-1H-吡唑-3-羧酸酯 甲基4,5-二氮杂螺[2.4]庚-5-烯-6-羧酸酯 甲基4,5-二氢-5-乙基-1H-吡唑-1-羧酸酯 甲基(E)-3-[6-[1-羟基-1-(4-甲基苯基)-3-(1-吡咯烷基)丙基]-2-吡啶基]丙烯酰酸酯 甲基(5-氧代-4,5-二氢-1,2-恶唑-3-基)乙酸酯 环戊二烯并[d]咪唑-2,5(1H,3H)-二硫酮 溶剂黄93 溴化1-十六烷基-3-甲基咪唑 溴化1-十二烷基-2,3-二甲基咪唑 泰比培南酯中间体 泰比培南酯中间体 氨基甲硫酸,[2-[[(2-羰基-1-咪唑烷基)硫代甲基]氨基]乙基]-,O-甲基酯 异噻唑,4,5-二氯-2,5-二氢-2-辛基- 希诺米啉 四氟硼酸二氢1,3-二(叔-丁基)-4,5--1H-咪唑正离子 四唑硝基紫 噻唑丁炎酮 噻唑,4,5-二氢-4-(1-甲基乙基)-,(S)- 噁唑,4,5-二氢-4,4-二甲基-2-(5-甲基-2-呋喃基)- 噁唑,2-庚基-4,5-二氢- 咪唑烷基脲 吡嗪,2,3-二氢-5,6-二甲基-2-丙基- 叔-丁基3-羟基-1,4,6,7-四氢吡唑并[4,3-c]吡啶-5-羧酸酯 双吡唑啉酮 双[(S)-4-异丙基-4,5-二氢噁唑-2-基]甲烷 双((R)-4-(叔丁基)-4,5-二氢恶唑-2-基)甲烷 利美尼啶D4 利美尼啶 假硫代乙内酰脲 依达拉奉杂质DO 依达拉奉杂质 依达拉奉三聚体 依达拉奉 仲班酸